top

Scientific Advisory Board




Jason Jungsik Song. M.D.

    Dr. Song received his M.D degree and pursued his fellowship in rheumatology from 1994 to 2001 at Yonsei University. Later the year, Dr. Song worked as research fellow at Massachusetts General Hospital in Boston and served as a medical resident in Internal Medicine at Metro West Medical Center in Framingham until 2004. He went to Stanford University School of Medicine and pursued as a Clinical fellow in Rheumatology, Post-doc and as well as Instructor in Division of Rheumatology/ Immunology until 2011. Dr. Song is currently an associate clinical professor in Division of Rheumatology at Yonsei University. Dr. Song is a board certified rheumatologist in both US and Korea. Dr. Song received ACR REF/AF Career Development Bridge Funding Award in 2008, NIH Mentored Clinical Scientist Research Career Development award in 2009, ACR Rheumatology Research Workshop Outstanding Abstract Award in 2009 and EAGOR young investigator award in 2013.

Sung-Hou Kim, Ph.D.

    Dr. Kim obtained his B.S. and M.S. in chemistry from Seoul National University, South Korea, and his Ph.D. from University of Pittsburgh. From 1966 to 1972 he was a researcher at the M.I.T., and he joined, in 1972, Duke University of School of Medicine as an assistant and associate professor for biochemistry. As a successful structural biologist and biophysicist, Dr. Kim is currently a professor at the Department of Chemistry, University of California, Berkeley, and a faculty scientist at Lawrence Berkeley National Laboratory. Furthermore, Dr. Kim is a member of the U.S. National Academy of Science and a fellow of the American Academy of Arts and Sciences since 1994. Major accomplishments of Dr. Kim are that he was the one of the researchers to report the first 3D structure of tRNA. Moreover, Dr. Kim co-founded the Plexxikon in 2001 where he developed Zelboraf® (vemurafenib), B-Raf enzyme inhibitor, for the treatment of late-stage melanoma. Plexxikon used a proprietary structural biology-based platform called Scaffold-Based Drug Discovery, and vermurafenib received the FDA approval for the treatment of late-stage melanoma, making it the first drug designed using fragment-based lead discovery to gain regulatory approval.

Yong Won Choi, Ph.D.

    Dr. Choi received his B.Sc. in 1984 at Seoul National University and Ph.D. (biochemistry) in 1988 at University of Illinois - College of Medicine. Dr. Choi completed his research fellowship in immunology at National Jewish Center. Subsequently, Dr. Choi served on the faculty of Rockefeller University and Howard Hughes Medical Institute. Currently, Dr. Choi is Leonard Jarett Professor of Pathology and Laboratory Medicine at University of Pennsylvania - School of Medicine. Dr. Choi is interested in the cellular and molecular mechanisms governing the homeostasis of bone and the immune system.

Jong-In Yook, D.D.S., Ph.D.

    Dr. Yook received his D.D.S. degree in 1987 and his Ph.D. (dental surgery) in 1995 at Yonsei College of Dentistry. Dr. Yook’s scientific background lies in surgical pathology and cell biology in metastasis of cancer. The major research interests include genetic mechanisms of EMT, Wnt signaling, and miRNA function during cancer metastasis. Presently, Dr. Yook is a professor at Department of Oral and Maxillofacial Pathology, Yonsei University - School of Dentistry.

Jae-Ho Cheong, M.D., Ph.D.

    Dr. Cheong received his M.D. degree in 1995 and his Ph.D. (surgical oncology, and tumor biology) in 2006 at Yonsei University, South Korea. Following a postdoctoral and Odyssey fellowship at UT MD Anderson Cancer Center, Dr. Cheong joined the Department of Surgery, at Yonsei Severance Hospital, as an associate professor.  Also, Dr. Cheong is a Vice Director for Office of Medical Science Research Affairs Academia - Industry Cooperation Foundation, at Yonsei University Health System.  Dr. Cheong’s research interests are in systems cancer biology,  tumor metabolism & epigenetics regulation in cancer metastasis, and development of molecular diagnostics for gastric cancer.

Aekyung Kim, Ph.D.

    Dr. Kim received her B.S. and M.S. degrees in pharmacy at Catholic University, South Korea. Dr. Kim also received M.S. (Toxicology) at University of Minnesota, and Ph.D. (molecular and environmental toxicology) at University of Wisconsin. Following her postdoctoral fellowship in Department of Neurology & Neurological Sciences at Stanford University, Dr. Kim joined the College of Pharmacy, at Catholic University, as a professor. Dr. Kim’s research interest is focused on the regulation of cellular physiology by mitochondrial redox states. Cellular redox status, either overall or mitochondrial, is known to regulate various cellular physiological processes. Therefore, redox status is likely to influence physiological processes of stem cell such as proliferation, differentiation and apoptosis. Adult stem cell inhabits microenvironment called 'niche'; its interaction with satellite cell is key in maintaining its 'stemness'. There are at least three directions from which redox-mediated stem cell regulation has to be approached: 1) redox status of stem cell itself, 2) redox status of ‘microenvironment/niche' and 3) redox status of satellite cell. Dr. Kim’s laboratory is currently conducting experiments to elucidate how redox status of niche influences asymmetrical and/or symmetrical division of stem cells.

Young Gun Shin, Ph.D.

    Dr. Shin received his B.S. in 1989 and Ph.D. (pharmacy) in 1997 at Seoul National University. Dr. Shin completed his post-doctoral research fellowship at University of Illinois at Chicago. After his education, Dr. Shin joined GlaxoSmithKline (GSK) in USA as a senior researcher between 2001 and 2004 followed by Genentech where he was involved in clinical research (ADME) for 10 years. Dr. Shin currently serves as an associate professor at Chungnam National University’s School of Pharmacy, and his research areas are in absolute bioavailability, mass balance and metabolite profiling/identification using nano-tracers, and drug development process utilizing in-silico, in-vitro, and in-vivo animal models to anticipate human PK/metabolism. Furthermore, by following US FDA, EMA, ICH guidelines he is currently working to develop accelerated early drug development strategies.